Next Article in Journal
Targeting Small Molecule Delivery to the Brain and Spinal Cord via Intranasal Administration of Rabies Virus Glycoprotein (RVG29)-Modified PLGA Nanoparticles
Next Article in Special Issue
Endoplasmic Reticulum-Associated Degradation-Dependent Processing in Cross-Presentation and Its Potential for Dendritic Cell Vaccinations: A Review
Previous Article in Journal
Treating Intracranial Abscesses in Rats with Stereotactic Injection of Biodegradable Vancomycin-Embedded Microparticles
Previous Article in Special Issue
Decellularized Lymph Node Scaffolding as a Carrier for Dendritic Cells to Induce Anti-Tumor Immunity
Open AccessReview

Therapeutic Cancer Vaccination with Ex Vivo RNA-Transfected Dendritic Cells—An Update

Department of Dermatology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Hartmannstraße 14, 91052 Erlangen, Germany
*
Author to whom correspondence should be addressed.
Pharmaceutics 2020, 12(2), 92; https://doi.org/10.3390/pharmaceutics12020092
Received: 13 December 2019 / Revised: 9 January 2020 / Accepted: 18 January 2020 / Published: 23 January 2020
(This article belongs to the Special Issue Dendritic Cell Vaccines)
Over the last two decades, dendritic cell (DC) vaccination has been studied extensively as active immunotherapy in cancer treatment and has been proven safe in all clinical trials both with respect to short and long-term side effects. For antigen-loading of dendritic cells (DCs) one method is to introduce mRNA coding for the desired antigens. To target the whole antigenic repertoire of a tumor, even the total tumor mRNA of a macrodissected biopsy sample can be used. To date, reports have been published on a total of 781 patients suffering from different tumor entities and HIV-infection, who have been treated with DCs loaded with mRNA. The majority of those were melanoma patients, followed by HIV-infected patients, but leukemias, brain tumors, prostate cancer, renal cell carcinomas, pancreatic cancers and several others have also been treated. Next to antigen-loading, mRNA-electroporation allows a purposeful manipulation of the DCs’ phenotype and function to enhance their immunogenicity. In this review, we intend to give a comprehensive summary of what has been published regarding clinical testing of ex vivo generated mRNA-transfected DCs, with respect to safety and risk/benefit evaluations, choice of tumor antigens and RNA-source, and the design of better DCs for vaccination by transfection of mRNA-encoded functional proteins. View Full-Text
Keywords: therapeutic vaccination; dendritic cells; RNA; electroporation; clinical trial; immunotherapy therapeutic vaccination; dendritic cells; RNA; electroporation; clinical trial; immunotherapy
Show Figures

Figure 1

MDPI and ACS Style

Dörrie, J.; Schaft, N.; Schuler, G.; Schuler-Thurner, B. Therapeutic Cancer Vaccination with Ex Vivo RNA-Transfected Dendritic Cells—An Update. Pharmaceutics 2020, 12, 92. https://doi.org/10.3390/pharmaceutics12020092

AMA Style

Dörrie J, Schaft N, Schuler G, Schuler-Thurner B. Therapeutic Cancer Vaccination with Ex Vivo RNA-Transfected Dendritic Cells—An Update. Pharmaceutics. 2020; 12(2):92. https://doi.org/10.3390/pharmaceutics12020092

Chicago/Turabian Style

Dörrie, Jan; Schaft, Niels; Schuler, Gerold; Schuler-Thurner, Beatrice. 2020. "Therapeutic Cancer Vaccination with Ex Vivo RNA-Transfected Dendritic Cells—An Update" Pharmaceutics 12, no. 2: 92. https://doi.org/10.3390/pharmaceutics12020092

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop